Tilray | TRLY - Gross Profit On Sales


Tilray reported $57.47M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Cronos Group USD 16.19M 34.52M Dec/2025
Dianthus Therapeutics USD 463K 179K Mar/2026
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
IQVIA Holdings USD 1.07B 52M Mar/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD -566M 792M Mar/2026
Organigram Holdings CAD 16.41M 6.91M Mar/2026
Organon & Co USD 783M 71M Mar/2026
Revvity USD 387.66M 34M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.38B 229.9M Mar/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026
Zealand Pharma A/S 68.91M 19.35M Dec/2025